Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2018 Apr 15.

Published in final edited form as: Clin Cancer Res. 2016 Oct 3;23(8):1981–1987. doi: 10.1158/1078-0432.CCR-16-0235

Table 2. Multivariate Analysis of Baseline TLG and MTV Scores on Clinical Outcomes (OS and PFS).

	Variable	Including TLG Scores			Including MTV Scores
	Variable	n/N (%)	HR (95% CI)	P-value	HR (95% CI)	P-value
OS	Baseline TLG > 620	12/176 (7%)	4.97 (2.42, 10.20)	<.0001
	Creatinine >= 2.0 mg/dL	11/176 (6%)	2.30 (1.05, 5.03)	0.0367
	LDH >= 190 U/L	52/176 (30%)	2.12 (1.31, 3.43)	0.0023	2.22 (1.37, 3.60)	0.0013
	B2M >5.5 mg/L	33/176 (19%)	1.83 (1.03, 3.25)	0.0397	2.914 (1.28, 3.76)	0.0042
	GEP Centrosome Index >= 3	57/176 (33%)	1.99 (1.22, 3.24)	0.0058
	Baseline MTV > 210	12/176 (7%)			5.49 (2.64, 11.40)	<.0001
	GEP Proliferation Index >= 10	22/176 (13%)			2.20 (1.21, 4.00)	0.0095
PFS	B2M > 5.5 mg/L	33/176 (19%)	1.76 (1.05, 2.95)	0.0329	1.75 (1.05, 2.94)	0.0334
	Creatinine >= 2.0 mg/dL	11/176 (6%)	2.47 (1.18, 5.18)	0.0161	2.47 (1.18, 5.17)	0.016
	LDH >= 190 U/L	57/176 (33%)	1.64 (1.04, 2.56)	0.0319	1.63 (1.04, 2.56)	0.0322
	GEP Centrosome Index >= 3	22/176 (13%)	1.62 (1.04, 2.52)	0.0348	1.61 (1.03, 2.52)	0.0353
	Baseline TLG > 620	12/176 (7%)	6.33 (3.07, 13.04)	<.0001
	Baseline MTV > 210	12/176 (7%)			6.38 (3.09, 13.19)	<.0001

HR- Hazard ratio, 95% CI – 95% Confidence Interval, p-value from Wald Chi-square test in Cox Regression